PATIENT REPORTED OUTCOMES OF UPADACITINIB: RESULTS FROM BIOLOGIC INADEQUATE RESPONDERS (SELECT BEYOND PHASE III TRIAL)

被引：0
|
作者：
Strand, V. [1 ]
Schiff, M. [2 ]
Tundia, N. [3 ]
Friedman, A. [3 ]
Meerwein, S. [3 ]
Pangan, A. [3 ]
Ganguli, A. [3 ]
Fuldeore, M. [3 ]
Song, Y. [4 ]
Pope, J. [5 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
[5] Univ Western Ontario, London, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1254
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0255
引用
收藏
页码：990 / 990
页数：1
相关论文
共 50 条
  • [1] Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
    Vibeke Strand
    Michael Schiff
    Namita Tundia
    Alan Friedman
    Sebastian Meerwein
    Aileen Pangan
    Arijit Ganguli
    Mahesh Fuldeore
    Yan Song
    Janet Pope
    Arthritis Research & Therapy, 21
  • [2] Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
    Strand, Vibeke
    Schiff, Michael
    Tundia, Namita
    Friedman, Alan
    Meerwein, Sebastian
    Pangan, Aileen
    Ganguli, Arijit
    Fuldeore, Mahesh
    Song, Yan
    Pope, Janet
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
  • [3] UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
    Strand, Vibeke
    Bergman, Martin
    Tundia, Namita
    Ostor, Andrew
    Durez, Patrick
    Song, In-Ho
    Enejosa, Jose Jeffrey
    Schlacher, Casey
    Song, Yan
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 738 - 739
  • [4] Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
    Bergman, Martin
    Tundia, Namita
    Camp, Heidi
    Meerwein, Sebastian
    Schlacher, Casey
    Goldschmidt, Debbie
    Song, Yan
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [5] Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
    Strand, Vibeke
    Tundia, Namita
    Wells, Alvin
    Buch, Maya H.
    Radominski, Sebastiao C.
    Camp, Heidi S.
    Friedman, Alan
    Suboticki, Jessica L.
    Dunlap, Kendall
    Goldschmidt, Debbie
    Bergman, Martin
    RHEUMATOLOGY, 2021, 60 (07) : 3209 - 3221
  • [6] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
    Strand, Vibeke
    Mease, Philip
    Soriano, Enrique
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Damjanov, Nemanja
    Anderson, Jaclyn K.
    Blondell, Erin
    Zueger, Patrick
    Saffore, Christopher
    Gladman, Dafna
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [7] Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis With Inadequate Response to Non-Biologic DMARDs Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 Study
    Gladman, Dafna
    Mease, Philip
    Soriano, Enrique
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Damjanov, Nemanja
    Anderson, Jaclyn
    Blondell, Erin
    Zueger, Patrick
    Saffore, Christopher
    Strand, Vibeke
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1168 - 1168
  • [8] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study
    Fleischmann, R.
    Meerwein, S.
    Charles-Schoeman, C.
    Combe, B.
    Hall, S.
    Khan, N.
    Carter, K.
    Camp, H.
    Rubbert-Roth, A.
    SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 26S
  • [9] Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
    Fleischmann, Roy
    Meerwein, Sebastian
    Charles-Schoeman, Christina
    Combe, Bernard
    Hall, Stephen
    Khan, Nasser
    Carter, Kyle
    Camp, Heidi
    Rubbert-Roth, Andrea
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 567 - 570
  • [10] Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
    Martin Bergman
    Namita Tundia
    Naomi Martin
    Jessica L. Suboticki
    Jayeshkumar Patel
    Debbie Goldschmidt
    Yan Song
    Grace C. Wright
    Arthritis Research & Therapy, 24
12345